MYMD-1®

About TNF Pharmaceuticals

TNF Pharmaceuticals is a publicly traded biotech firm pivoting from its former identity as MyMD Pharmaceuticals, with a core focus on immunometabolic modulation to treat aging and inflammatory diseases. Its most advanced asset, MYMD-1®, has shown positive Phase 2 results in sarcopenia/frailty and is being prepared for Phase 3 trials, positioning it as a potential first-in-class treatment for this condition. In a significant strategic shift, the company recently secured exclusive global rights to a light-based computing accelerator for cryptocurrency applications, signaling a venture into high-performance computing alongside its therapeutic pipeline. This dual-track strategy introduces both novel opportunity and substantial execution risk.

About TNF Pharmaceuticals

TNF Pharmaceuticals is a publicly traded biotech firm pivoting from its former identity as MyMD Pharmaceuticals, with a core focus on immunometabolic modulation to treat aging and inflammatory diseases. Its most advanced asset, MYMD-1®, has shown positive Phase 2 results in sarcopenia/frailty and is being prepared for Phase 3 trials, positioning it as a potential first-in-class treatment for this condition. In a significant strategic shift, the company recently secured exclusive global rights to a light-based computing accelerator for cryptocurrency applications, signaling a venture into high-performance computing alongside its therapeutic pipeline. This dual-track strategy introduces both novel opportunity and substantial execution risk.

About TNF Pharmaceuticals

TNF Pharmaceuticals is a publicly traded biotech firm pivoting from its former identity as MyMD Pharmaceuticals, with a core focus on immunometabolic modulation to treat aging and inflammatory diseases. Its most advanced asset, MYMD-1®, has shown positive Phase 2 results in sarcopenia/frailty and is being prepared for Phase 3 trials, positioning it as a potential first-in-class treatment for this condition. In a significant strategic shift, the company recently secured exclusive global rights to a light-based computing accelerator for cryptocurrency applications, signaling a venture into high-performance computing alongside its therapeutic pipeline. This dual-track strategy introduces both novel opportunity and substantial execution risk.

Therapeutic Areas